West Pharmaceutical Services Stock Price To Earning
| WST Stock | USD 343.91 4.34 1.28% |
West Pharmaceutical Services fundamentals help investors to digest information that contributes to West Pharmaceutical's financial success or failures. It also enables traders to predict the movement of West Stock. The fundamental analysis module provides a way to measure West Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to West Pharmaceutical stock.
West |
West Pharmaceutical Services Company Price To Earning Analysis
West Pharmaceutical's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current West Pharmaceutical Price To Earning | 40.71 X |
Most of West Pharmaceutical's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, West Pharmaceutical Services is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, West Pharmaceutical Services has a Price To Earning of 40.71 times. This is 57.55% higher than that of the Health Care Equipment & Supplies sector and 11.99% higher than that of the Health Care industry. The price to earning for all United States stocks is 41.75% lower than that of the firm.
West Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses West Pharmaceutical's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of West Pharmaceutical could also be used in its relative valuation, which is a method of valuing West Pharmaceutical by comparing valuation metrics of similar companies.West Pharmaceutical is currently under evaluation in price to earning category among its peers.
West Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 24.41 B | ||||
| Shares Outstanding | 72.42 M | ||||
| Shares Owned By Insiders | 0.58 % | ||||
| Shares Owned By Institutions | 96.96 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| Price To Earning | 40.71 X | ||||
| Price To Book | 8.94 X | ||||
| Price To Sales | 8.55 X | ||||
| Revenue | 2.95 B | ||||
| Gross Profit | 1 B | ||||
| EBITDA | 844.1 M | ||||
| Net Income | 593.4 M | ||||
| Cash And Equivalents | 894.3 M | ||||
| Cash Per Share | 9.85 X | ||||
| Total Debt | 309 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 3.80 X | ||||
| Book Value Per Share | 37.96 X | ||||
| Cash Flow From Operations | 776.5 M | ||||
| Short Ratio | 2.78 X | ||||
| Earnings Per Share | 6.72 X | ||||
| Price To Earnings To Growth | 6.34 X | ||||
| Target Price | 379.85 | ||||
| Number Of Employees | 10.6 K | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 24.59 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | 3.52 B | ||||
| Working Capital | 1.26 B | ||||
| Current Asset | 673.7 M | ||||
| Current Liabilities | 314.3 M | ||||
| Annual Yield | 0 % | ||||
| Five Year Return | 0.36 % | ||||
| Net Asset | 3.83 B | ||||
| Last Dividend Paid | 0.8 |
About West Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze West Pharmaceutical Services's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of West Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of West Pharmaceutical Services based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.